CLINICAL TRIALS PROFILE FOR ISOTRETINOIN

All Clinical Trials for ISOTRETINOIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000764 ↗	Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.	Completed	Hoffmann-La Roche	Phase 1	1969-12-31	PRIMARY: In Phase I, to define a broadly tolerable dose of isotretinoin that can be used in combination with interferon alfa-2a (IFN alfa-2a). In Phase II, to determine trends in efficacy of isotretinoin alone or in combination with IFN alfa-2a as chemoprevention (preventing progression or recurrence) of anal intraepithelial neoplasia ( AIN ) / squamous intraepithelial lesions ( SIL ) in patients with HIV infection. SECONDARY: To evaluate the effects of isotretinoin alone or in combination with IFN alfa-2a on immune function markers, human papillomavirus (HPV) type, and HPV DNA levels. Patients with HIV infection have a significant risk of recurrence following local ablation of intraepithelial neoplasia; thus, anogenital epithelial may become an increasingly important cause of morbidity, and possibly mortality, as the HIV epidemic matures. Clinical studies of non-HIV-infected subjects have established that synthetic retinoids inhibit the progression of epithelial preneoplastic conditions and some neoplastic states.
NCT00000764 ↗	Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	PRIMARY: In Phase I, to define a broadly tolerable dose of isotretinoin that can be used in combination with interferon alfa-2a (IFN alfa-2a). In Phase II, to determine trends in efficacy of isotretinoin alone or in combination with IFN alfa-2a as chemoprevention (preventing progression or recurrence) of anal intraepithelial neoplasia ( AIN ) / squamous intraepithelial lesions ( SIL ) in patients with HIV infection. SECONDARY: To evaluate the effects of isotretinoin alone or in combination with IFN alfa-2a on immune function markers, human papillomavirus (HPV) type, and HPV DNA levels. Patients with HIV infection have a significant risk of recurrence following local ablation of intraepithelial neoplasia; thus, anogenital epithelial may become an increasingly important cause of morbidity, and possibly mortality, as the HIV epidemic matures. Clinical studies of non-HIV-infected subjects have established that synthetic retinoids inhibit the progression of epithelial preneoplastic conditions and some neoplastic states.
NCT00001073 ↗	Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	The purpose of this study is to see if it is safe and effective to give isotretinoin to HIV-infected women with cervical tumors to prevent these tumors from becoming cancerous. Cervical tumors are found in both HIV-infected and HIV-negative women. However, HIV-infected women are at a greater risk, and often their tumors become cancerous more quickly than those in HIV-negative women. Isotretinoin may be able to prevent this from happening. However, since these tumors tend to disappear over time, many doctors are hesitant to give their patients isotretinoin since this drug causes birth defects. This study looks at whether it is better to treat cervical tumors in HIV-infected women or to wait and see if they will disappear by themselves.
NCT00002506 ↗	Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer	Completed	Cancer Biotherapy Research Group	Phase 2	1992-08-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of isotretinoin may be an effective way to prevent cancer or stop cancer from growing. Interferon alfa may interfere with the growth of cancer cells. Combining isotretinoin and interferon may be an effective treatment for some recurrent cancers. PURPOSE: Phase II trial to study the effectiveness of interferon alfa plus isotretinoin in treating patients with recurrent cancer.
NCT00002506 ↗	Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer	Completed	Hoag Memorial Hospital Presbyterian	Phase 2	1992-08-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of isotretinoin may be an effective way to prevent cancer or stop cancer from growing. Interferon alfa may interfere with the growth of cancer cells. Combining isotretinoin and interferon may be an effective treatment for some recurrent cancers. PURPOSE: Phase II trial to study the effectiveness of interferon alfa plus isotretinoin in treating patients with recurrent cancer.

Clinical Trial Conditions for ISOTRETINOIN

Condition Name

Condition Name for ISOTRETINOIN
Intervention	Trials
Neuroblastoma	29
Acne Vulgaris	23
Acne	10
Recurrent Neuroblastoma	8

Condition MeSH

Condition MeSH for ISOTRETINOIN
Intervention	Trials
Neuroblastoma	41
Acne Vulgaris	33
Leukemia	7
COVID-19	7

Clinical Trial Locations for ISOTRETINOIN

Trials by Country

Trials by Country for ISOTRETINOIN
Location	Trials
United States	691
Canada	61
Australia	28
Egypt	13
France	13

Trials by US State

Trials by US State for ISOTRETINOIN
Location	Trials
California	34
Pennsylvania	33
Texas	28
New York	28
Massachusetts	26

Clinical Trial Progress for ISOTRETINOIN

Clinical Trial Phase

Clinical Trial Phase for ISOTRETINOIN
Clinical Trial Phase	Trials
PHASE4	7
PHASE3	4
PHASE1	2

Clinical Trial Status

Clinical Trial Status for ISOTRETINOIN
Clinical Trial Phase	Trials
Completed	78
Recruiting	23
Not yet recruiting	18

Clinical Trial Sponsors for ISOTRETINOIN

Sponsor Name

Sponsor Name for ISOTRETINOIN
Sponsor	Trials
National Cancer Institute (NCI)	39
Children's Oncology Group	11
Kafrelsheikh University	7

Sponsor Type

Sponsor Type for ISOTRETINOIN
Sponsor	Trials
Other	179
NIH	46
Industry	36

Isotretinoin: Clinical Trials Update, Market Analysis, and Supply-Projections

Last updated: April 26, 2026

What is the current clinical-trials landscape for isotretinoin?

Isotretinoin’s clinical development base is mature, with most global activity focused on (i) formulation changes, (ii) dosing convenience, (iii) safety-program optimization under pregnancy prevention and monitoring systems, and (iv) niche indications or subpopulations. Trial volume remains lower than it was during first-generation approvals, but regulatory follow-ons and investigator-led studies persist across dermatology.

Execution pattern

• Core regimen: oral isotretinoin for severe nodular acne, typically using weight-based dosing and fixed cumulative exposure targets in label-based practice.
• Ongoing clinical work: refinement of adherence, absorption/bioavailability expectations across formulations, and risk-management execution under iPLEDGE-like pregnancy prevention frameworks in the US and equivalent national systems elsewhere.
• Trial design trend: smaller, shorter studies for formulation and patient-experience endpoints, alongside observational real-world safety studies tied to teratogenic risk management compliance.

What that means for decision-makers

• The “pipeline” is less about new mechanism innovation and more about how isotretinoin is delivered, monitored, and made safer administratively.
• Near-term upside is driven more by formulation differentiation, generics competition dynamics, and access policies than by new systemic breakthroughs.

Is isotretinoin a “brand-to-brand” competitive market or a commodity generics market?

Isotretinoin is structurally a generics-dominated systemic acne drug in most developed markets, with long-running brand presence historically, and persistent generic substitution. That structure makes the market more sensitive to:

• pricing pressure,
• formulary access,
• pregnancy-prevention program execution costs,
• supply reliability of oral solid dose products.

Commercial reality

• When patents and exclusivities expire, isotretinoin quickly shifts to a multi-entrant generic floor.
• Differentiation tends to appear in formulation, packaging, and compliance workflows rather than clinical efficacy, because the efficacy envelope is well established.

How big is the isotretinoin market and what segments matter?

Isotretinoin is sold primarily for:

• Acne vulgaris (severe, nodulocystic)
• Adjunct or off-label dermatology use in certain jurisdictions (varies by regulator and payer policy)
• Special populations (adolescents and adults) where pregnancy prevention requirements strongly shape access logistics in women of childbearing potential

Market segmentation that affects projections

1. Indication segment
   • Severe acne treatment drives the majority of use, but demand is filtered by clinical criteria (severity thresholds) and prescriber comfort with monitoring.
2. Geography
   • High prescription throughput markets are sensitive to generic penetration and reimbursement rules.
   • Countries with strict pregnancy-prevention administration can add friction even when clinical need is high.
3. Formulation
   • Immediate-release oral products dominate; variation comes from dose strengths, capsule vs gel-caps formats, and excipient profiles that can shift tolerability.
4. Care pathway
   • Utilization depends on how quickly patients can access prescriber visits, labs (liver enzymes/lipids depending on protocol), and compliance enrollment.

What drives near-term growth or contraction?

Demand supports

• Persistent global prevalence of severe acne.
• Long disease duration and recurring flares in subsets of patients.
• Established efficacy that remains hard to replace pharmacologically for severe disease.

Headwinds

• Strict pregnancy prevention frameworks increase administrative burden and can limit initiation or continuation rates.
• Price compression after generic entry reduces revenue per patient.
• Safety monitoring costs and patient adherence complexity remain real constraints.

Net effect on projections

• Volume growth tracks population and dermatologist throughput, but value growth is limited in many markets by generic pricing.
• Growth often shows up as:
  • higher treated prevalence (more patients reach treatment),
  • more efficient administrative programs lowering drop-off,
  • supply stability reducing treatment interruptions.

What does the supply-demand outlook look like for isotretinoin?

Isotretinoin supply is typically robust because the molecule is mature and widely manufactured globally. The key risks are not technological scarcity; they are operational:

• batch-to-batch consistency for oral solid dose products,
• GMP compliance incidents at specific sites,
• raw material availability and excipient constraints,
• packaging and distribution constraints in seasonal demand surges (typically aligned with dermatology visits cycles).

Projection logic for supply

• Baseline expectation: stable supply with periodic spot constraints.
• Competitive manufacturing footprint: multiple generic suppliers reduce systemic risk.
• Demand elasticity: moderate, with initiation constrained more by administrative and prescribing criteria than by pure availability.

What should investors and R&D leaders watch for next?

1) Regulatory and risk-management execution improvements

• Systems that reduce friction in pregnancy prevention workflows can increase initiation and completion rates, which lifts realized demand.
• Compliance automation and prescriber training can shift adherence.

2) Formulation differentiation that impacts tolerability

• Even when efficacy is established, tolerability drives continuation and dosing tolerance, especially for higher-dose regimens or patients sensitive to dryness and lab monitoring.

3) Pricing and channel access

• Generic competition determines margin structure.
• Payer formularies and reimbursement rules can swing volumes between suppliers.

Clinical trials update: how to interpret “activity” in isotretinoin now

Given isotretinoin’s mature status, “clinical trials activity” should be interpreted as:

• Formulation and bioequivalence: supports substitution and access, often not a major clinical novelty driver.
• Safety and adherence: evaluates how to maintain risk management compliance while improving patient experience.
• Subpopulation work: supports dosing precision (weight bands, pediatric-adolescent workflows, or specific comorbidity management).

A useful business lens is to track:

• trial counts per year by geography,
• endpoints: bioequivalence, pharmacokinetics, patient-reported tolerability, or safety compliance,
• recruitment status and submission timelines to regulators.

Market projection framework for isotretinoin (what moves the curve)

Because isotretinoin is a mature, generics-driven therapy, market projections should be built around four levers:

Lever	What to measure	Directional impact
Treated prevalence	Severe acne diagnosis and dermatology throughput	Up
Initiation funnel	Pregnancy prevention workflow friction	Down if restrictive; up if streamlined
Completion adherence	Tolerability and monitoring logistics	Up
Realized price	Generic penetration and tender outcomes	Down if more entrants

Projection conclusion

• Volume: tends to be stable-to-up in many markets, constrained mainly by care access and administrative steps.
• Revenue: tends to grow slower or decline in mature markets due to price erosion, with exceptions where access programs, tenders, or fewer entrants support pricing.

Key diligence checklist for R&D and licensing on isotretinoin

1. Regulatory pathway alignment
   • Ensure labeling and safety program requirements match local risk-management frameworks.
2. Formulation stability and consistency
   • Focus on excipient profile and dissolution characteristics that can affect tolerability and PK.
3. Patient access and compliance design
   • Evaluate how product packaging and patient support programs integrate into pregnancy prevention systems.
4. Payer and formulary strategy
   • Model channel behavior by geography using tender and reimbursement history.

Key Takeaways

• Isotretinoin clinical development is mature; current trial activity concentrates on formulation, adherence, safety program execution, and patient workflow rather than new mechanism breakthroughs.
• The market is largely generics-driven, so demand volume is influenced more by access and compliance execution than by clinical differentiation.
• Future value growth is constrained by pricing pressure, while upside comes from workflow streamlining, tolerability improvements, and supply reliability.
• Supply outlook is typically stable with operational risks that can create short-term constraints rather than structural shortages.

FAQs

1. What type of clinical trials are most common for isotretinoin today?
   Formulation/bioequivalence studies, PK refinement, and safety or adherence work linked to risk-management compliance.

2. Why do pregnancy prevention programs materially affect isotretinoin demand?
   They increase initiation friction and administrative steps for patients of childbearing potential, which can reduce start and completion rates.

3. Is isotretinoin a high-innovation pipeline opportunity?
   The core innovation is established; current opportunities are more about execution, formulation tolerability, and market access than new therapeutic mechanism.

4. What usually drives revenue performance for isotretinoin in mature markets?
   Generic pricing, formulary access, and tender outcomes typically dominate over clinical differentiation.

5. Are supply shortages common for isotretinoin?
   Systemic shortages are uncommon due to broad manufacturing, but localized constraints can occur from manufacturing or regulatory incidents at specific sites.

---

References

[1] U.S. Food and Drug Administration. iPLEDGE Program. (FDA webpage). https://www.ipledgeprogram.com/
[2] European Medicines Agency. Roaccutane (isotretinoin) and product information resources (EMA). https://www.ema.europa.eu/
[3] U.S. Food and Drug Administration. ROACCUTANE (isotretinoin) Prescribing Information (current label text). https://www.accessdata.fda.gov/